Bolt Biotherapeutics, Inc. Payments to Acquire Marketable Securities
Bolt Biotherapeutics, Inc. (BOLT) reported Payments to Acquire Marketable Securities of $1.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $1.23M, a 23.99% increase year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $11.84M, a 10.66% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $1.72M, a 91.54% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $29.02M, a 67.34% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $88.86M, a 46.14% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $164.99M, a 8.70% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $180.70M, a 42.34% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.23M 10-Q · filed 2026-08-11 | $13.07M derived: sum of 3 quarters · filed 2026-08-11 | $14.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-12 | $13.07M derived: sum of 2 quarters · filed 2026-05-12 | $14.79M derived: sum of 3 quarters · filed 2026-05-12 | $29.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $11.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $13.56M derived: sum of 2 quarters · filed 2026-03-12 | $28.02M derived: sum of 3 quarters · filed 2026-08-11 | $29.02M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.18M derived: sum of 2 quarters · filed 2026-08-11 | $17.18M 10-Q · filed 2025-11-12 | $30.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $14.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $15.46M 10-Q · filed 2026-08-11 | $28.71M derived: sum of 3 quarters · filed 2026-08-11 | $49.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $992.00K 10-Q · filed 2026-05-12 | $14.24M derived: sum of 2 quarters · filed 2026-05-12 | $34.56M derived: sum of 3 quarters · filed 2026-05-12 | $66.79M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $13.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $33.57M derived: sum of 2 quarters · filed 2026-03-12 | $65.80M derived: sum of 3 quarters · filed 2026-03-12 | $88.86M 10-K · filed 2026-03-12 |
| 2024-09-30 | $20.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $52.54M derived: sum of 2 quarters · filed 2025-11-12 | $75.60M 10-Q · filed 2025-11-12 | $107.76M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $32.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $55.28M 10-Q · filed 2025-08-14 | $87.44M derived: sum of 3 quarters · filed 2025-08-14 | $123.75M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $23.06M 10-Q · filed 2025-05-12 | $55.22M derived: sum of 2 quarters · filed 2025-05-12 | $91.52M derived: sum of 3 quarters · filed 2025-05-12 | $145.16M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $32.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $68.46M derived: sum of 2 quarters · filed 2025-03-24 | $122.11M derived: sum of 3 quarters · filed 2025-03-24 | $164.99M 10-K · filed 2025-03-24 |
| 2023-09-30 | $36.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $89.94M derived: sum of 2 quarters · filed 2024-11-12 | $132.83M 10-Q · filed 2024-11-12 | $158.19M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $53.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $96.52M 10-Q · filed 2024-08-13 | $121.88M derived: sum of 3 quarters · filed 2024-08-13 | $169.79M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $42.88M 10-Q · filed 2024-05-14 | $68.24M derived: sum of 2 quarters · filed 2024-05-14 | $116.15M derived: sum of 3 quarters · filed 2024-05-14 | $147.50M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $25.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $73.27M derived: sum of 2 quarters · filed 2024-03-21 | $104.62M derived: sum of 3 quarters · filed 2024-03-21 | $180.70M 10-K · filed 2024-03-21 |
| 2022-09-30 | $47.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $79.26M derived: sum of 2 quarters · filed 2023-11-09 | $155.34M 10-Q · filed 2023-11-09 | $185.03M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $31.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $107.43M 10-Q · filed 2023-08-07 | $137.12M derived: sum of 3 quarters · filed 2023-08-07 | $173.04M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $76.08M 10-Q · filed 2023-05-11 | $105.77M derived: sum of 2 quarters · filed 2023-05-11 | $141.69M derived: sum of 3 quarters · filed 2023-05-11 | $191.39M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $29.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $65.61M derived: sum of 2 quarters · filed 2023-03-29 | $115.31M derived: sum of 3 quarters · filed 2023-03-29 | $313.38M 10-K · filed 2023-03-29 |
| 2021-09-30 | $35.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $85.62M derived: sum of 2 quarters · filed 2022-11-10 | $283.69M 10-Q · filed 2022-11-10 | $283.69M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $49.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $247.77M 10-Q · filed 2022-08-10 | $247.77M derived: sum of 3 quarters · filed 2022-08-10 | $267.76M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $198.07M 10-Q · filed 2022-05-12 | $198.07M derived: sum of 2 quarters · filed 2022-05-12 | $218.06M derived: sum of 3 quarters · filed 2022-05-12 | $218.06M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $19.99M derived: sum of 2 quarters · filed 2022-03-30 | $19.99M derived: sum of 3 quarters · filed 2022-03-30 | $33.23M 10-K · filed 2022-03-30 |
| 2020-09-30 | $19.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $19.99M derived: sum of 2 quarters · filed 2021-11-09 | $33.23M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $13.23M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $13.23M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |